Korean Red Ginseng extract reduces hypoxia-induced epithelial-mesenchymal transition by repressing NF-κB and ERK1/2 pathways in colon cancer

Eui Joo Kim1, Kwang An Kwon1,2, Young Eun Lee1, Ju Hyun Kim1, Se-Hee Kim2,**, Jung Ho Kim1,2,*

1Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Republic of Korea
2Gachon Medical Research Institute, Gachon University Gil Medical Center, Incheon, Republic of Korea

1. Introduction

Colorectal cancer (CRC) is the second most commonly diagnosed cancer in men and the third in women in South Korea [1]. Moreover, CRC incidence in South Korea is increasing at a rate of approximately 6% per year [1]. Notably, metastatic status, including locoregional node-positive at newly diagnosed CRC, has been reported in 57% of CRC patients [2].

Due to high oxygen requirements of rapid cell proliferation, solid tumors, such as CRC, often contain hypoxic regions and structurally and functionally unusual intratumoral blood vessels [3]. Intratumoral hypoxia induces the accumulation of hypoxia-inducible factor-1α (HIF-1α), a protein that is rapidly degraded by the ubiquitin–proteasome system under normoxic conditions [3,4]. HIF-1α plays a key role in tumor progression, therapeutic resistance, invasiveness, and metastasis [5–7].

In the initial stages of metastasis, cancer cells separate from the main tumor sites, migrate, and invade the surrounding tissue, i.e. lymphatic and blood vessels. During the epithelial-mesenchymal transition (EMT), epithelial cells lose their cell-cell junctions and polarity, acquiring migratory and invasive abilities and displaying mesenchymal cell phenotype [8]. EMT is an important cellular
event that enables malignant cells in the primary tumor to invade other tissues and metastasize [8,9]. Importantly, EMT is mainly triggered by tumor hypoxia [7,8].

Korean Red Ginseng (RG) (Panax ginseng Meyer) is commonly used in Asian traditional medicine to treat various diseases [10]. Two-thirds of cancer patients in Korea take dietary supplements; of these, 50% have reported taking an RG product [11,12]. Korean RG extract (KRGE) has long been used in tonics and rejuvenation remedies [13]. Although beneficial anti-cancer activity of KRGE has been reported in vitro and in vivo, detailed molecular mechanisms of the anti-tumor effects are not well understood [14–16].

Although a few studies have reported detailed molecular mechanisms of anti-metastatic effects of KRGE in CRC, the effects of KRGE on the EMT process in CRC metastasis are unknown. Therefore, the aim of this study was to evaluate the effects of KRGE on hypoxia-induced EMT in CRC cell lines.

2. Materials and methods

2.1. Reagents

KRGE was manufactured by Korea Ginseng Corporation (Seoul, South Korea) from six-year-old Korean RG plants (P. ginseng). The roots of Korean RG were extracted by steaming fresh Korean Ginseng harvested in South Korea at 50–100 °C for 3 h and then drying the plant material at 50–80 °C. KRGE was extracted at 85–90 °C for 8 h by circulating hot water through it three times. The water content of the collected extract was 36% of the total weight. MG132 and deferoxamine (DFO) were obtained from Sigma-Aldrich (St. Louis, MO, USA). DMSO was used to dissolve MG132. KRGE and deferoxamine (DFO) were obtained from Sigma-Aldrich (St. Louis, MO, USA). DMSO was used to dissolve MG132. KRGE and DFO were dissolved in water.

2.2. Cell lines and hypoxic conditions

HT29 and HCT116 human colon cancer cells were obtained from the Korean Cell Line Bank (Seoul, South Korea). The cells were cultured in McCoy’s 5A medium (Gibco, Carlsbad, CA, USA) with 1% penicillin streptomycin (Gibco) and 10% fetal bovine serum (FBS; Gibco), at 37 °C in a 5% CO2 humidified incubator. To generate hypoxic conditions, the cells were incubated in a hypoxic incubator. To generate hypoxic conditions, the cells were incubated in a hypoxic incubator (New Brunswick Scientific, Edison, NJ, USA) with 1% O2 and 5% CO2 balanced with 94% N2.

2.3. MTT cell proliferation assay

KRGE-treated cells were incubated in 96-well plates for 24–96 h. The MTT reagent (Sigma-Aldrich) (5 mg/mL) was diluted in McCoy’s medium. After 90 min of incubation, the medium was replaced by 100 μL of DMSO. Absorbance was measured at 570 nm. The IC50 values of KRGE were derived from dose-response curves using GraphPad Prism 3.05 (San Diego, CA, USA).

2.4. Western blot analysis

For cell lysis, RIPA buffer (50mM Tris–HCl at pH 8.0; 0.1% SDS; 0.5% sodium deoxycholate; 150mM NaCl; 1% NP-40; protease inhibitors) and whole cell lysis buffer (0.1mM EDTA; 400mM NaCl; 10mM HEPES at pH 7.9; 0.1mM EDTA; 1mM DTT; 5% glycerol; protease inhibitors) were used. Nuclear and cytoplasmic fractions were extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Scientific, Rockford, IL, USA). Anti-HIF-1α antibody (1:1000) and anti-integrin αVβ6 antibody (1:1000) were obtained from Novus Biologicals (Littleton, CO, USA). Antibodies to E-cadherin (1:5000), phospho-p65 (1:1000), p65 (1:1000), phospho-ERK1/2 (1:1000), ERK1/2 (1:1000), phospho-p38 (1:1000), p38 (1:1000), phospho-JNK (1:1000), JNK (1:1000), phospho-STAT3 (1:1000), STAT3 (1:1000), histone H3 (1:1000), and GAPDH (1:1000) were purchased from Cell Signaling (Beverly, MA, USA). Anti-β-actin antibody (1:5000) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The samples were normalized to β-actin using Image J software.

2.5. Quantitative real-time PCR (qRT-PCR)

QRT-PCR was conducted on a CFX96 detection system (BioRad, Hercules, CA, USA) with SYBR Green as the marker (Takara Bio Inc., Otsu, Shiga, Japan). Primers for the qRT-PCR reaction are listed in Table 1. The fold change in expression of target gene was calculated using GAPDH as reference. The experiment was performed in triplicate.

2.6. Immunocytochemistry

Cells treated with KRGE for 5–7 days were plated on coverslips coated with 0.1% gelatin [17]. After fixing in 3.7% paraformaldehyde for 15 min, the cancer cells were permeabilized in 0.5% Triton X-100/PBS for 5 min, and blocked in 1% BSA/PBS-T (0.1% Triton X-100/PBS) for 30 min. After incubation with anti-E-cadherin antibody diluted in 1% BSA/PBS-T for 1 h at room temperature, the cells were washed with PBS and incubated with Alexa Fluor 555 (Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature. Cell nuclei were stained with DAPI (Vector Laboratories Inc., Burlingame, CA, USA) and the images were processed using a LSM710 confocal microscope (Carl Zeiss, Jena, Germany).

2.7. Scratched wound healing assay

Cells were cultured to 80–90% confluence in 60 mm plates and wounded using a tip. Afterwards, the cells were washed with PBS to remove non-adherent cells and incubated in McCoy’s medium with

| Table 1 |
| --- |
| Nucleotide sequences of qRT-PCR primers |

| Targets of PCR | Forward primers (5’–3’) | Reverse primer (5’–3’) |
| --- | --- | --- |
| Snail | CCC CAACCTG GAA GCC TAA CT | GCT GGA AGG TAA ACT GTG TAG TAT A |
| Slug | ACC CCC AGC TCA CTA GTG | CCC CAA GAT CAG GAG TAT A |
| Twist | GGC CTT GGG AAG ATC TTC | GCT GTG CAT CTT GCT CAG TTG |
| VEGF | ATC TTC ACA CCA TCC TCT GTG C | CAA GCC CCA CAG GGA TTT TC |
| PHD1 | AGG CTT CTC AAG CAT TGG TCG | GGG ATT TAC CAG CTG CAC CTT |
| PHD2 | AAG CCC AGT TGT CAG ACA TT | TTA CGG ACC GAA TCA GAG G |
| PHD3 | AGG AGC TCT TGC TGG CAA GCT | GAT TAC AGA GCA CGG TCA GTC |
| VHL | AGC GGC GTC GAA GAG TAC G | CCG ACT GCC ATT GCA GAA GA |
| GAPDH | AGG TCG GAC TCA AGC CAT TGG | ACA GTC TTC TGG GTG GCA GTG ATG |
**Fig. 1.** Cytotoxic effects of KRGE on colon cancer cell lines. (A, B) Cell viability of HT29 and HCT116 cells treated with KRGE (0.1, 0.25, 0.5, 1, 2.5, 5, and 10 mg/mL) for 24–96 h was estimated using the MTT assay. Data are represented as mean ± SD (n = 6). KRGE, Korean Red Ginseng extract.

**Fig. 2.** Effects of KRGE on expression of VEGF mRNA and HIF-1α protein levels in HT29 and HCT116 cells under hypoxic conditions. (A, B) Total RNA was isolated from cells treated with KRGE (1 and 2 mg/mL) and/or hypoxic incubation for 72 h (A) or 24 h (B). VEGF mRNA levels were analyzed by qRT-PCR. VEGF mRNA expression was reduced in HT29 and HCT116 cancer cells treated with KRGE under hypoxia. (C, D) HIF-1α expression in cancer cells treated with KRGE (0.5, 1, and 2 mg/mL) and/or hypoxia for 24 h was examined using western blot. HIF-1α protein expression was reduced in KRGE-treated HT29 and HCT116 cells under hypoxia. *p < 0.05, **p < 0.01 versus normoxia control groups. *p < 0.05, **p < 0.01 versus hypoxia-only groups. KRGE, Korean Red Ginseng extract; VEGF, vascular endothelial growth factor; HIF-1α, hypoxia-inducible factor-1α.
1–2 mg/mL KRGE and/or 100 μM DFO for 48 h. Cell images were recorded at 0 and 48 h (CFX41, Olympus, Tokyo, Japan). The percentage of migrating cells was determined with Image J software as previously described [17]. The experiment was performed in triplicate.

### 2.8 Transwell migration assay

KRGE-treated cells were plated into transwells with 0.2% gelatin coated surface and exposed to hypoxia for 24 h [17]. FBS (20%) in the bottom chamber was used as a chemoattractant. After fixation with methanol for 2 min, the cells were stained with hematoxylin/eosin for 10 min. Thereafter, the cells on the upper membrane were removed with a wet cotton swab, whereas the cells on the lower membrane were mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA) and counted under a DP72 microscope (Olympus). The data were normalized to control group values. The experiment was performed in triplicate.

### 2.9 Matrigel invasion assay

After coating the lower surfaces with 0.2% gelatin for 1 h at room temperature and upper membranes with matrigel (BD Biosciences, San Jose, CA, USA) for 2 h at 37°C, KRGE-treated cells in the transwells were subjected to hypoxia for 48 h, with 20% FBS in the bottom chamber used as chemoattractant. After fixation with methanol and staining with hematoxylin/eosin, the cells on the lower surfaces were counted under an Olympus DP72 microscope. The data were normalized to the control group. The experiment was performed in triplicate.
2.10. Statistical analysis

Data were analyzed with SPSS 23.0 software (IBM Corporation, Armonk, NY, USA). Significant differences between groups were assessed using a paired t-test. P-values < 0.05 were considered statistically significant.

3. Results

3.1. KRGE decreases VEGF mRNA levels and HIF-1α protein expression

In order to examine cytotoxic effects of KRGE on colon cancer cells, HT29 and HCT116 cells were incubated with KRGE at various concentrations for 24–96 h, and cell viability was determined using the MTT assay (Fig. 1). As shown in Fig. 1, changes in IC50 values over 24–96 h were detected in both cell lines. In order to determine whether KRGE regulates the expression of hypoxia-related genes, HT29 and HCT116 cells were treated with 0.5–2 mg/mL KRGE and incubated under hypoxia for 72 h (A–C) or 24 h (D–F). Transcripts of Snail (A, D), Slug (B, E), and Twist (C, F) were repressed in HT29 and HCT116 cancer cells treated with KRGE under hypoxic conditions. (G, H) αVβ6 integrin expression in cells treated with KRGE (0.5, 1, and 2 mg/mL) and/or hypoxic incubation for 7 (G) or 5 days (H) was examined by western blot. Fold changes of αVβ6 integrin expression were normalized to β-actin. αVβ6 integrin was repressed in KRGE-treated HT29 and HCT116 cells in hypoxic conditions. *p < 0.05, **p < 0.01 versus normoxia control groups. *p < 0.05, **p < 0.01 versus hypoxia-only groups. KRGE, Korean Red Ginseng extract; EMT, epithelial-mesenchymal transition; N, normoxia.
degradation in both cell lines treated with KRGE (Fig. 3A–B), suggesting that KRGE may reduce HIF-1α stability in a proteasome-dependent manner.

Finally, in order to elucidate whether KRGE regulated the expression of von Hippel-Lindau (VHL) protein and prolyl hydroxylases (PHDs), which mediate HIF-1α degradation, mRNA levels of VHL and PHDs in KRGE-treated cells were examined using qRT-PCR. No statistically significant change in VHL and PHDs mRNA levels was observed upon KRGE treatment in either of the cell lines, compared to hypoxia controls (Fig. 3C, D).

3.2. KRGE inhibits EMT markers expression under hypoxia

To determine whether KRGE could modulate EMT in hypoxic conditions, KRGE-treated HT29 and HCT116 cells were incubated under hypoxia for 72 or 24 h. Transcription of Snail, Slug, and Twist increased in hypoxic conditions and was decreased by KRGE treatment. Inhibitory effects of KRGE on mRNA levels of EMT markers in HT29 and HCT116 cells were as follows: in HT29 cells, Snail (36–46%, \( p < 0.05 \) and \( p < 0.01 \) versus hypoxia control groups), Slug (52–59%, \( p < 0.05 \) and \( p < 0.01 \) versus hypoxia control groups), and Twist (53–74%, both \( p < 0.05 \) versus hypoxia control groups); in HCT116 cells, Snail (36–57%, both \( p < 0.01 \) versus hypoxia control groups), Slug (5–47%, both \( p < 0.01 \) versus hypoxia control groups), and Twist (63–82%, both \( p < 0.01 \) versus hypoxia control groups) (Fig. 4A–F).

The effect of KRGE on expression of \( \alpha V \beta 6 \) integrin, a mesenchymal phenotype marker in colon cancer, was also explored. As shown in Fig. 4G–H, \( \alpha V \beta 6 \) integrin expression increased under hypoxia, whereas the expression of \( \alpha V \beta 6 \) integrin in KRGE-treated HT29 and HT116 cells was inhibited by 60 and 92%, respectively.

3.3. KRGE reverts hypoxia-induced morphological changes

Next, we evaluated whether KRGE could restore morphological characteristics of cells altered by hypoxic treatment. In order to perform this experiment, KRGE-treated HT29 and HCT116 cells were incubated under hypoxia for 7 or 5 days. Unlike normoxic HT29 and HCT116 cells, which were round and clustered together, hypoxia-exposed cells were scattered and elongated (Fig. 5A, C). Importantly, treatment with KRGE partially restored cell morphology to one reminiscent of cells grown under normoxia. Moreover, we found that E-cadherin protein levels that had been inhibited by hypoxia, recovered by 33 and 26% in KRGE-treated HT29 and HCT116 cells, respectively (Fig. 5B, D).

3.4. KRGE diminishes invasiveness of colon cancer cells under hypoxia

The scratched wound healing assay was performed in HT26 and HCT116 cells in order to assess whether KRGE regulates migration of colorectal cancer cells. A hypoxia mimicking reagent, DFO, was used. As shown in Fig. 6, DFO-treated HT29 and HCT116 cells showed enhanced migration compared to untreated groups, whereas migration of cells treated with DFO and KRGE was reduced. Specifically, KRGE showed a 56–71% \( (p < 0.05 \) versus DFO-
only control groups) and 44–89% (p < 0.05 and p < 0.01 versus hypoxia control groups) decrease in wound recovery, in hypoxic HT29 and HCT116 cells, respectively. To confirm this suppressive effect of KRGE, we conducted the transwell migration assay. KRGE showed 38–78% (p < 0.05 versus hypoxia control groups) and 19–63% (p < 0.05 versus hypoxia control groups) decrease in migration of HT29 and HCT116 cells, respectively (Fig. 7A–B).

Finally, we performed the invasion assay to assess whether KRGE regulated the invasion of colon cancer cells. As shown in Fig. 7C–D, KRGE-treated HT29 and HCT116 cells displayed a 29–59% (p < 0.05 versus hypoxia control groups) and a 32–62% (p < 0.05 versus hypoxia control groups) reduction of invasion under hypoxia, respectively.

3.5. **KRGE represses the activation of NF-κB and ERK1/2 under hypoxia**

To identify cellular signaling pathways regulated by KRGE during the hypoxia-induced EMT, we examined various pathways in the KRGE-treated HT29 and HCT116 cells using western blot. KRGE-treated HT29 and HCT116 cells dramatically reduced hypoxia-induced phosphorylation of p65 and ERK1/2 (Fig. 8A–B). To
confirm the inhibitory effect of KRGE on activation of p65, we examined cellular localization of p65 using nuclear and cytoplasmic fractions from KRGE-treated cells. As shown in Fig. 8C–D, KRGE inhibited the translocation of p65, but not STAT3.

4. Discussion

In cancer patients, metastases are among the main causes of death. Suppressing migratory and invasive abilities of cancer cells is especially important in colon cancer patients as distant metastasis is particularly common in CRC. Hypoxic control of EMT is notably associated with cancer progression, metastasis, and resistance to therapy [5,18]. Moreover, HIF-1α has been reported as an important regulator of EMT in several cancer cell lines [5,6,18].

In the current study, we hypothesized that KRGE suppresses migratory and invasive properties of colon cancer cells by repressing hypoxia-induced EMT. Our results indicate that KRGE inhibits hypoxic induction of VEGF by destabilizing HIF-1α protein. HIF-1α degradation results from proline hydroxylation by PHDs, which promotes binding to VHL protein, a component of the large E3 ubiquitin ligase complex, resulting in proteasomal degradation of HIF-1α. In our study, KRGE did not reduce HIF-1α stability in MG132-
treated cells and did not affect mRNA levels of VHL and PHDs under hypoxia, indicating that KRGE may not control the expression of genes involved in HIF-1α degradation, instead controlling the steps of the HIF-1α degradation pathway, such as ubiquitylation. However, Choi et al. suggested that RG inhibits hypoxic induction of HIF-1 target genes through dissociation of HIF-1 dimer without affecting HIF-1α stability in liver cancer and immortalized normal cells [14]. These conflicting results may result from organ specificity. Therefore, further studies are required to examine organ-specificity of KRGE-mediated regulation of HIF-1α stability.

According to our results, KRGE treatment inhibited expression of EMT markers Snail, Slug, and αVβ6 integrin under hypoxic conditions. In addition, KRGE partially restored E-cadherin expression and reversed morphologic cell changes induced by hypoxic conditions. The process of EMT is involved in early embryogenesis, tissue fibrosis, and movement of metastatic cancer cells. Many of the molecules that trigger the EMT process have been identified, including Snail and Slug, transcription factors of target genes involved in HIF-1α degradation, instead controlling the steps of HIF-1α degradation pathway, such as ubiquitylation. However, Choi et al. suggested that RG inhibits hypoxic induction of HIF-1 target genes through dissociation of HIF-1 dimer without affecting HIF-1α stability in liver cancer and immortalized normal cells [14]. These conflicting results may result from organ specificity. Therefore, further studies are required to examine organ-specificity of KRGE-mediated regulation of HIF-1α stability.

Loss of E-cadherin expression is an important prototypical event in EMT [19]. In addition, colon cancer cells undergoing EMT show high levels of αVβ6 integrin [20]. For these reasons, we monitored E-cadherin and αVβ6 integrin expression levels in colon cancer cells. Incubation of cells for 5–7 days under hypoxia was required to detect morphological changes associated with the EMT process. KRGE increased E-cadherin in cancer cells under hypoxic conditions, and decreased αVβ6 integrin levels.

NF-κB is a regulator of apoptosis, proliferation, angiogenesis, and metastasis [21,22]. Recent studies suggest that hypoxia induces NF-κB activity in IKK- and TAK1-dependent manner [21], and activates the MAPK/ERK1/2 pathway that induces EMT-like phenotypes in hepaticocellular carcinoma cells [23,24]. In this study, KRGE repressed hypoxia-induced phosphorylation of NF-κB and ERK1/2 in colon cancer cells, indicating that KRGE may block metastasis of colon cancer cells through inhibition of NF-κB and ERK1/2. However, RG was reported to decrease metastasis of colon cancer cells by attenuating MMP-2 and MMP-9 pathways [25]. Therefore, RG may reduce invasion and metastasis of colon cancer cells via NF-κB and ERK1/2 pathways in hypoxic conditions and MMP-2/9 pathways in normoxic conditions.

CRC is associated with two major classes of genetic instability, chromosome instability (microsatellite stable; MSS) and microsatellite instability (MSI) [26]. HT29 and HCT116 cancer cell lines were used in the present study as they belong to MSS and MSI cell lines, respectively. Our study of KRGE anti-metastatic effects in two different genetic signatures provides guidance for in vivo studies and clinical trials addressing KRGE-related molecular mechanisms.

Toxicity to healthy cells often limits the clinical utility of chemotherapeutic agents. As natural products, such as ginseng extracts, may present anti-cancer activity with reduced toxicity, it is important to elucidate the anti-cancer effects of KRGE.

In conclusion, KRGE inhibits hypoxia-induced EMT by repres- sing the activation of NF-κB and ERK1/2 pathways in colon cancer cells and may be potentially beneficial in the treatment of colon cancer.

Conflicts of interest

The authors have no conflicts of interests to disclose.

Acknowledgments

This work was supported by the Gachon University Gil Medical Center (Grant number: 2014-19-02).

References

[1] Jung KW, Won YJ, Hong WK, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013;45:1–14.
[2] Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al., editors. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 2014. p. 1975–2011. Available from: http://seer.cancer.gov/csr/1975_2011/.
[3] Tang CM, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer. J Gastroenterol Hepatol 2013;28:401–5.
[4] Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465–72.

[5] Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 2012;1826:272–96.

[6] Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009;107:1053–62.

[7] Marie-Egyptienne DT, Löhse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 2013;341:63–72.

[8] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420–8.

[9] Natalwala A, Spychal R, Tselepis C. Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract. World J Gastroenterol 2013;19:4866–72.

[10] Lee SM, Bae BS, Park HW, Ahn NG, Cho BG, Cho YL, Kwak YS. Characterization of Korean Red Ginseng (Panax ginseng Meyer): history, preparation method, and chemical composition. J Ginseng Res. 2015;39:384–91.

[11] Kang HP, Lee H, Oh TG, Lee KJ, Park SJ, Chung MJ, Kim SU, Lee H, Park JY, Park JY, et al. The use of health functional foods in gastrointestinal cancer patients. Clin Nutr Res 2013;2:19–25.

[12] Kim BC, Song YM, Park SJ, Kim SY, Gwak JI. Use of dietary supplements in cancer patients. Korean J Fam Med 2009;30:632–40.

[13] Baeg IH, So SH. The world ginseng market and the ginseng [Korea]. J Ginseng Res 2013;37:1–7.

[14] Choi YJ, Choi H, Cho CH, Park JW. Red ginseng deregulates hypoxia-induced genes by dissociating the HIF-1 dimer. J Nat Med 2011;65:344–52.

[15] Liu T, Zhao L, Zhang Y, Chen W, Liu D, Hou H, Ding L, Li X. Ginsenoside 20(S)-Rg3 targets HIF-1alpha to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells. PLoS One 2014;9:e103887.

[16] Choi KS, Song H, Kim EH, Choi JH, Hong H, Han YM, Hahn KB. Inhibition of hydrogen sulfide-induced angiogenesis and inflammation in vascular endothelial cells: potential mechanisms of gastric cancer prevention by Korean Red Ginseng. J Ginseng Res 2012;36:135–45.

[17] Kim JH, Hwang YJ, Han SH, Lee YE, Kim S, Kim YJ, Cho JH, Kwon KA, Kim JH, Kim SH. Dexmethasone inhibits hypoxia-induced epithelial-mesenchymal transition in colon cancer. World J Gastroenterol 2015;21:9887–99.

[18] Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225–39.

[19] Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429–37.

[20] Bates RC, Bellovin DR, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettingen P, Mercurio AM. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339–47.

[21] Culver C, Sundqvist A, Mude S, Melvin A, Xiromanis D, Rocha S. Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol 2010;30:4901–21.

[22] Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680–4.

[23] Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T, Rosa R, Indelicato M, Fini M, Pucci B, et al. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-kappaB. Carcinogenesis 2011;32:1167–75.

[24] Li X, Wang X, Zhang P, Zhu L, Zhao T, Liu S, Wu Y, Chen X, Fan M. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in inhibition of myogenic differentiation of myoblasts by hypoxia. Exp Physiol 2012;97:257–64.

[25] Seo EY, Kim WK. Red ginseng extract reduced metastasis of colon cancer cells in vitro and in vivo. J Ginseng Res. 2011;35:315–24.

[26] Giacomini CP, Leung SY, Chen X, Yuen ST, Kim YH, Bair E, Pollack JR. A gene expression signature of genetic instability in colon cancer. Cancer Res 2005;65:9200–5.